BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 3119650)

  • 1. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary and ovarian response to acute stimulation with LH-RH in normal and anovulatory women.
    Aparicio NJ; Casas PR; Galimberti DM; de Laborde NP; Badano A; GarcĂ­a EP; Meichi HR; Mirkin A; Szejner M; Jaitt A; Margulies M; Rosner JM
    Int J Fertil; 1977; 22(1):6-15. PubMed ID: 18416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some aspects on pituitary function in human and rat anovulatory cycles.
    Makino T; Shiina M; Ohno T; Iizuka R; Tamaoki B
    Endocrinol Jpn; 1976 Dec; 23(6):445-9. PubMed ID: 798684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.
    Couzinet B; Young J; Kujas M; Meduri G; Brailly S; Thomas JL; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4191-6. PubMed ID: 10566671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
    Waldstreicher J; Santoro NF; Hall JE; Filicori M; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous administration of low-dose GnRH in mares II. Pituitary and ovarian responses to uninterrupted treatment beginning near the autumnal equinox and continuing throughout the anovulatory season.
    Collins SM; Zieba DA; Williams GL
    Theriogenology; 2007 Sep; 68(4):673-81. PubMed ID: 17590426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
    Saffan D; Seibel MM
    Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse.
    Couse JF; Bunch DO; Lindzey J; Schomberg DW; Korach KS
    Endocrinology; 1999 Dec; 140(12):5855-65. PubMed ID: 10579351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
    Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
    J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.